Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Surrozen, Inc./DESRZN · Entity 6092 | Chief Scientific Officer | June 15, 2023 | June 20, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Surrozen, Inc./DE
Report date June 15, 2023 · Filed June 20, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,216 |
Reported balance
After 2023-06-15 transaction · row 1
1 source rowRow 1 · 2023-06-15 · Grant · Acquired 17,638 · Balance 27,216 F1: These shares were acquired under the Surrozen, Inc. 2021 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired under the Surrozen, Inc. 2021 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2023 Filed Jun 20, 2023 06:02 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | GrantCommon Stock | 17,638 | $0.38 | $6,702.44 |
DisclosureSEC source: 0001593968-23-001020 · primary_01.xml · nonDerivative · entry 1 Yeh Wen-Chen · CIK 0001873360 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,216 F1 · kind: These shares were acquired under the Surrozen, Inc. 2021 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 16:28 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | GrantOption (right to buy) · Derivative | 125,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001593968-23-000264 · primary_01.xml · derivative · entry 1 Yeh Wen-Chen · CIK 0001873360 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-02-01 F1 · derivative.exercise_date: The shares subject to the options vest and become exercisable in a series of 48 equal monthly installments beginning on 2/1/2023, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
| December 15, 2022 Filed Dec 19, 2022 19:09 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | GrantCommon Stock | 9,578 | $0.41 | $3,926.98 |
DisclosureSEC source: 0001593968-22-001750 · primary_01.xml · nonDerivative · entry 1 Yeh Wen-Chen · CIK 0001873360 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,138 F1 · kind: These shares were acquired under the Surrozen, Inc. 2021 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| October 10, 2022 Filed Oct 12, 2022 21:59 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | GrantOption (right to buy) · Derivative | 29,567 | Not disclosed Strike: $2.16 | Not disclosed |
DisclosureSEC source: 0001593968-22-001520 · primary_01.xml · derivative · entry 5 Yeh Wen-Chen · CIK 0001873360 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,567 Underlying: Common Stock · 29,567 shares Expires 2031-02-22 F1 · price: The reporting person agreed to cancellation of an option granted to him on February 23, 2021, in exchange for a new option having a lower exercise price. F2 · derivative.exercise_date: The shares subject to the options vest and become exercisable in a series of 48 equal monthly installments beginning on 2/1/2021, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
| October 10, 2022 Filed Oct 12, 2022 21:59 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | GrantOption (right to buy) · Derivative | 5,562 | Not disclosed Strike: $2.16 | Not disclosed |
DisclosureSEC source: 0001593968-22-001520 · primary_01.xml · derivative · entry 4 Yeh Wen-Chen · CIK 0001873360 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,562 Underlying: Common Stock · 5,562 shares Expires 2031-02-22 F1 · price: The reporting person agreed to cancellation of an option granted to him on February 23, 2021, in exchange for a new option having a lower exercise price. F2 · derivative.exercise_date: The shares subject to the options vest and become exercisable in a series of 48 equal monthly installments beginning on 2/1/2021, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
| October 10, 2022 Filed Oct 12, 2022 21:59 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | Disposition to issuerOption (right to buy) · Derivative | 5,562 | Not disclosed Strike: $10.77 | Not disclosed |
DisclosureSEC source: 0001593968-22-001520 · primary_01.xml · derivative · entry 2 Yeh Wen-Chen · CIK 0001873360 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,562 shares Expires 2031-02-22 F1 · price: The reporting person agreed to cancellation of an option granted to him on February 23, 2021, in exchange for a new option having a lower exercise price. F2 · derivative.exercise_date: The shares subject to the options vest and become exercisable in a series of 48 equal monthly installments beginning on 2/1/2021, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
| October 10, 2022 Filed Oct 12, 2022 21:59 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | Disposition to issuerOption (right to buy) · Derivative | 29,567 | Not disclosed Strike: $10.77 | Not disclosed |
DisclosureSEC source: 0001593968-22-001520 · primary_01.xml · derivative · entry 1 Yeh Wen-Chen · CIK 0001873360 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,567 shares Expires 2031-02-22 F1 · price: The reporting person agreed to cancellation of an option granted to him on February 23, 2021, in exchange for a new option having a lower exercise price. F2 · derivative.exercise_date: The shares subject to the options vest and become exercisable in a series of 48 equal monthly installments beginning on 2/1/2021, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
| July 01, 2022 Filed Oct 12, 2022 21:59 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | GrantOption (right to buy) · Derivative | 500 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001593968-22-001520 · primary_01.xml · derivative · entry 3 Yeh Wen-Chen · CIK 0001873360 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Underlying: Common Stock · 500 shares Expires 2032-07-01 F3 · derivative.exercise_date: The shares subject to the options vest and become exercisable in a series of 48 equal monthly installments beginning on 7/21/2022, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 20:59 UTC | Surrozen, Inc./DE SRZN · Entity 6092 | GrantOption (right to buy) · Derivative | 125,000 | $0.00 Strike: $3.11 | $0.00 |
DisclosureSEC source: 0001593968-22-000639 · primary_01.xml · derivative · entry 1 Yeh Wen-Chen · CIK 0001873360 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Surrozen, Inc. Common Stock · 125,000 shares Expires 2032-03-01 F1 · derivative.exercise_date: The shares subject to the options vest and become exercisable in a series of 48 equal monthly installments beginning on 2/1/2022, subject to the reporting person's continued employment through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.